ClinicalTrials.gov
ClinicalTrials.gov Menu

Pilot Study Assessing Insulin Pump Therapy in Type 2 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00922649
Recruitment Status : Completed
First Posted : June 17, 2009
Last Update Posted : September 21, 2017
Sponsor:
Information provided by (Responsible Party):
Animas Corporation

March 13, 2008
June 17, 2009
September 21, 2017
February 1, 2008
December 1, 2008   (Final data collection date for primary outcome measure)
  • Insulin doses at Week 16 [ Time Frame: Week 16 ]
    To evaluate insulin doses after 16 weeks of insulin pump therapy aimed at achieving normal or near-normal glycemic control in subjects with type 2 diabetes.This included the total daily insulin dose, basal and bolus insulin doses.
  • Ratio of Basal-to-Bolus Insulin Dose at Week 16 [ Time Frame: 16 weeks ]
    Evaluate insulin dosing patterns after 16 weeks of insulin pump therapy aimed at safely achieving normal or near-normal glycemic control in patients with type 2 diabetes
  • Number of daily basal rates at Week 16 [ Time Frame: Week 16 ]
    To evaluate insulin dosing patterns, i.e., number of daily basal rates, after 16 weeks of insulin pump therapy aimed at achieving normal or near-normal glycemic control in subjects with type 2 diabetes.
To evaluate insulin doses and dosing patterns after 16 weeks of insulin pump therapy aimed at achieving normal or near-normal glycemic control in subjects with type 2 diabetes. [ Time Frame: 16 weeks ]
Complete list of historical versions of study NCT00922649 on ClinicalTrials.gov Archive Site
  • A1C (Hemoglobin A1c) [ Time Frame: Week 16 ]
    To evaluate the effect of 16 weeks of insulin pump therapy in subjects with type 2 diabetes on glycemic outcome
  • 7 point profile [ Time Frame: Week 16 ]
    Self-monitored 7-point profiles were compared at baseline and Week 16 for each cohort and all cohorts combined.
  • CGM Glucose Ranges - Percent of Measurements [ Time Frame: End of study ]
    The percent of glucose values within the target range of 70-180 mg/dL, as measured by CGM
  • Body Weight [ Time Frame: Week 16 ]
    Weight change was evaluated at Week 16 for each cohort and all cohorts combined.
  • Hypoglycemia [ Time Frame: Week 16 ]
    The incidence (percent of patients with at least one episode of hypoglycemia) of minor hypoglycemia was evaluated respectively. Minor hypoglycemia was defined as symptoms consistent with hypoglycemia that either resolved spontaneously or upon self-treatment with oral carbohydrate. Severe hypoglycemia referred to symptoms consistent with hypoglycemia during which the patient required the assistance of another individual and was associated with a documented glucose concentration less than 56 mg/dL or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon.
  • Change from baseline to week 16 in Patient Reported Outcomes (PROs) [ Time Frame: Week 16 ]
    PROs were assessed at Baseline, Wk 8 (except for EQ-5D) and Wk 16, including EuroQol-5 Dimensions (EQ-5D) (Generic health-related QoL), Diabetes Symptom Checklist-Revised (DSC-R) (Diabetes-specific QoL), and Insulin Delivery System Rating Questionnaire (IDSRQ) (Treatment Satisfaction with insulin delivery system)
To evaluate the effect of 16 weeks of insulin pump therapy in subjects with type 2 diabetes on:A1C, Fasting and postprandial glucose,Glycemic variability, Body weight, Patient Reported Outcomes (PROs), Hypoglycemia frequency and severity, and AEs [ Time Frame: 16 weeks ]
Not Provided
Not Provided
 
Pilot Study Assessing Insulin Pump Therapy in Type 2 Diabetes
Pilot Study Assessing Insulin Pump Therapy in Type 2 Diabetes
16-week, open-label, multi-center pilot study. Insulin pump naïve subjects with type 2 diabetes who are not achieving glycemic targets (screening A1C ≥ 7.0%) on an established regimen of either: 1) ≥ 2 OAs (Cohort A), 2) basal insulin ± OAs (Cohort B), or 3) basal-bolus insulin ± OAs (Cohort C) will initiate basal-bolus therapy with an insulin pump using a rapid-acting insulin analog.
Not Provided
Interventional
Not Applicable
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Device Feasibility
Type 2 Diabetes
Device: Insulin Pump therapy
Initiation of Insulin pump therapy in patients on >2 OAs (Cohort A), basal insulin ± OAs (Cohort B), or basal-bolus insulin ± OAs (Cohort C.
  • A
    Insulin pump naïve subjects with type 2 diabetes who are not achieving glycemic targets (screening A1C ≥ 7.0%) on an established regimen of ≥ 2 OAs
    Intervention: Device: Insulin Pump therapy
  • B
    Insulin pump naïve subjects with type 2 diabetes who are not achieving glycemic targets (screening A1C ≥ 7.0%) on an established regimen of basal insulin ± OAs
    Intervention: Device: Insulin Pump therapy
  • C
    Insulin pump naïve subjects with type 2 diabetes who are not achieving glycemic targets (screening A1C ≥ 7.0%) on an established regimen basal-bolus insulin ± OAs
    Intervention: Device: Insulin Pump therapy

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
58
Same as current
January 1, 2009
December 1, 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Is 18 to 75 years of age, inclusive;
  2. Has a clinical diagnosis of type 2 diabetes mellitus;
  3. Is anti-glutamic acid decarboxylase (GAD) antibody negative;
  4. Has an A1C ≥ 7.0% and ≤ 10.5%;
  5. Has a body mass index (BMI) ≥ 25 kg/m2 and ≤ 40 kg/m2;
  6. Is treated with either ≥ 2 oral antidiabetic agents (OA) or basal insulin ± OA(s) or basal-bolus insulin ± OA(s) for at least 3 months (Subjects may also be treated with exenatide [Byetta] or pramlintide [Symlin].
  7. If on concomitant metformin, has serum creatinine < 1.5 mg/dL (male) or <1.4 mg/dL (female);
  8. If female, has a negative urine pregnancy test

Exclusion Criteria:

  1. Has experienced recurrent severe hypoglycemia (> 2 episodes) requiring assistance during the past 6 months;
  2. Has clinical cardiovascular disease (CVD) as evidenced by prior myocardial infarction, stroke, arterial revascularization and/or angina with ischemic changes on ECG at rest, changes on graded exercise test, or positive cardiac imaging test results;
  3. Has abnormalities on the screening (Visit 1) 12-lead ECG that are deemed by the investigator to be clinically significant;
  4. Is currently being treated with or expected to require or undergo treatment with systemic steroids by oral, intravenous, or intramuscular route or potent inhaled,intrapulmonary, intranasal, or topical steroids that are known to have a high rate of systemic absorption;
  5. Currently abuses drugs or alcohol or has a history of abuse that in the investigator's opinion would cause the individual to be non-compliant;
  6. Has any significant medical condition, laboratory findings, or medical history that in the investigator's opinion may affect successful completion of the study and/or personal well-being;
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Older Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00922649
ANM002
No
Not Provided
Not Provided
Animas Corporation
Animas Corporation
Not Provided
Principal Investigator: Timothy Bailey, MD AMCR Institute, Inc.
Principal Investigator: Bruce Bode, MD Atlanta Diabetes Associates, Inc.
Principal Investigator: Mark Kipnes, MD dgd Research, Inc.
Principal Investigator: John Liljenquist, MD Rocky Mountain Diabetes and Osteoporosis Center, PA
Principal Investigator: Lyle Myers, M.D Kentucky Diabetes Endocrinology Center
Principal Investigator: Sunder Mudaliar, MD University of California, San Diego
Animas Corporation
September 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP